Supine hypertension is a common finding in autonomic failure that can worsen orthostatic hypotension and predispose to end-organ damage. This review focuses on nonpharmacologic and pharmacologic approaches to manage hypertension in these patients in the face of disabling orthostatic hypotension.
INTRODUCTION
Autonomic failure patients are a clear example of how crucial the autonomic nervous system is in the regulation of blood pressure. The clinical hallmark of autonomic failure is disabling orthostatic hypotension; however, at least half of these patients also have supine hypertension, which can be severe and associated with end-organ damage. This review will focus on management approaches of supine hypertension in patients with primary forms of autonomic failure who also suffer from orthostatic hypotension. These are relatively rare medical conditions, but lessons learned can be applied to the common situation of the elderly patient who develops orthostatic hypotension.
CLINICAL PRESENTATION AND PATHOPHYSIOLOGY OF PRIMARY AUTONOMIC FAILURE
Primary autonomic failure is a neurodegenerative condition associated with cellular lesions involving protein inclusions rich in a-synuclein. The two main types of autonomic failure are classified depending on whether autonomic lesions are of central (multiple systems atrophy, MSA) versus peripheral (pure autonomic failure, PAF) origin. In MSA patients, protein inclusions are present in the cytoplasm of glial cells in the striatonigral system to produce parkinsonian features or in olivopontocerebellar structures resulting in cerebellar signs of truncal ataxia. In both cases there is often involvement of brainstem regions that participate in autonomic cardiovascular modulation (Shy-Drager syndrome) [1, 2] . MSA patients have normal plasma norepinephrine levels and noradrenergic innervation of the heart, indicating that peripheral sympathetic fibers are intact and provide a tonic sympathetic discharge that cannot be modulated because of impaired central autonomic pathways [3, 4] . In contrast, PAF is associated with protein precipitates that form Lewy bodies in spinal cord neurons, autonomic ganglia and peripheral noradrenergic fibers [5, 6] . Histologically, the neural involvement with Lewy bodies is identical to classical Parkinson's disease [7] , but PAF patients do not exhibit movement disorders. On the other hand, patients with Parkinson's disease or with dementia of Lewy body disease often have autonomic abnormalities with orthostatic hypotension, and all three conditions are likely part of a spectrum of disease [8, 9] . PAF patients have very low plasma norepinephrine levels and loss of noradrenergic innervation to the heart, indicating peripheral sympathetic denervation [3, 4] . Despite these pathophysiologic differences, the clinical picture of both MSA and PAF is dominated by disabling orthostatic hypotension due to inadequate vasoconstriction and excessive venous pooling [10] . The loss of the baroreceptor reflex function in autonomic failure also exacerbates the inability to control for blood pressure changes resulting in exaggerated responses to pressor and depressor stimuli that would produce little effect in healthy individuals [11, 12] .
PARADOXICAL SUPINE HYPERTENSION IN AUTONOMIC FAILURE
In addition to profound orthostatic hypotension, at least half of autonomic failure patients have high blood pressure while lying down. The supine hypertension can be severe with levels greater than 200 mmHg [11, 13] . This phenomenon often goes undetected, as blood pressure is usually measured only in the seated position when it is likely to be normal. The severity of supine hypertension is positively associated with the magnitude of orthostatic hypotension [14] . Supine hypertension may result from treatment with long-acting pressor agents including the mineralocorticoid fludrocortisone, but is also seen in untreated patients. It is unclear whether these patients develop de-novo hypertension, or if they had preexisting essential hypertension that is unmasked or worsened by loss of baroreflex buffering. The presence of hypertension in autonomic failure has numerous deleterious consequences. It can limit the use of pressor agents for the treatment of orthostatic hypotension; it increases nocturnal pressure natriuresis inducing volume depletion and worsening of morning orthostatic hypotension; and it is associated with end-organ damage. Longitudinal studies are not available, but cross-sectional studies show an increased prevalence of left ventricular hypertrophy and renal impairment in autonomic failure patients with supine hypertension [15] [16] [17] .
The pathophysiology of hypertension in autonomic failure varies depending on the disease type. As mentioned previously, patients with MSA have residual sympathetic tone that is ineffectual in preventing orthostatic hypotension because it cannot be modulated to increase in response to gravitational stress. On the contrary, this residual sympathetic tone contributes to hypertension in MSA because blood pressure is entirely normalized by the ganglion blocker trimethaphan [18] . Although it seems paradoxical that sympathetic activity could contribute to hypertension in autonomic failure, this phenomenon is likely explained by the residual sympathetic activity acting on hypersensitive adrenoreceptors and unrestrained due to ineffective baroreflexes. MSA patients also have enhanced pressor responses to yohimbine, an a 2 -adrenoreceptor antagonist that increases norepinephrine release [18] , and to the norepinephrine reuptake blocker atomoxetine [19] , further suggesting that the residual sympathetic tone can be engaged to elevate blood pressure.
In contrast, sympathetic-independent mechanisms are more important in PAF because their hypertension is less responsive to ganglionic blockade [18] . The supine hypertension in PAF is not
KEY POINTS
About half of patients with autonomic failure patients have supine hypertension, which can be severe, associated with end-organ damage, and can worsen orthostatic hypotension by inducing pressure natriuresis.
Pressor agents used to treat orthostatic hypotension should never be given while the patient is supine because this provides no clinical benefit and further aggravates orthostatic hypotension through pressure diuresis.
Supine hypertension is treated during the day by avoiding the supine posture and during the night by elevating the head of the bed by 6-9 inches.
Ambulatory 24-h monitoring is useful to guide treatment because in many patients blood pressure dips during the night and may not require further treatment.
Those with sustained nocturnal hypertension can be treated with nitroglycerin patch applied at bedtime and removed in the morning, or with sildenafil or shortacting nifedipine given at bedtime.
explained by changes in intravascular volume or cardiac output, as previous studies show no differences in patients with or without supine hypertension [11, 20] . The hypertension in PAF appears to be driven by increased vascular resistance [21] , but the factors responsible for this vasoconstriction are not known. PAF patients have very low levels of plasma norepinephrine and plasma renin activity, but plasma aldosterone levels are normal [22] , which could independently contribute to elevations in blood pressure [23] . Nitric oxide is another metabolic factor that tonically lowers blood pressure in humans [24] , and nitric oxide deficiency has been proposed to contribute to the development of essential hypertension [25] . It is not clear, however, if nitric oxide deficiency contributes to hypertension in the absence of autonomic function [26] and whether nitric oxide function is increased rather than impaired in autonomic failure patients with supine hypertension [27] .
MANAGEMENT APPROACHES FOR THE SUPINE HYPERTENSION OF AUTONOMIC FAILURE
During the daytime, the most effective means to prevent hypertension is to avoid the supine position. This seemingly obvious recommendation is often overlooked. Patients can sit in a reclining chair with feet on the floor if rest is needed. It is especially important to avoid the supine position while using methods to treat orthostatic hypotension such as abdominal binders, compression stockings and pressor agents. The use of pressor agents is a common cause of supine hypertension, particularly in hospitalized patients who are given medications at fixed intervals while they are confined to bed to prevent falls. This mismanagement leads to aggravation of supine hypertension, pressure diuresis with volume loss and worsening of orthostatic hypotension, creating a vicious cycle that can render patients disabled. Instead, pressor agents should be given as needed, approximately 30-45 min before upright activities, to allow patients to be active for 2-4 h at a time. It should be remembered that the goal of pressor agents is to reduce orthostatic symptoms and improve quality of life, not to treat the underlying disease. As such, it is often sufficient to use pressor agents only in the morning and early afternoon when symptoms are worse, and patients should be instructed not to lie down for at least 3-4 h after each dose. Fludrocortisone is frequently required to treat patients with severe orthostatic hypotension, but this comes at the expense of worsening of supine hypertension. In less severe patients, it may be worth determining whether short-acting pressor agents are sufficient to improve orthostatic symptoms. Also, autonomic failure patients should be instructed to avoid overthe-counter medications that increase blood pressure such as nasal decongestants or eye drops containing sympathomimetics, and NSAIDs such as indomethacin and ibuprofen [28] .
If these recommendations are followed, most patients do not require treatment of hypertension during the day. In our practice, we do not even monitor supine blood pressures during the day, and guide our daytime treatment using seated blood pressure measurements. A few patients are hypertensive while seated, and this greatly complicates their management. Although there are no controlled studies that would guide treatment of patients with seated hypertension, calcium channel blockers and arterial vasodilators, such as hydralazine, can be tried.
In most patients, supine hypertension only needs to be treated during the night. Automated 24-h ambulatory blood pressure monitoring is useful in guiding treatment in these patients [29] . A significant proportion of patients may have supine hypertension at bedtime, but their blood pressure may dip during the night to normal values, and pharmacological treatment may not be justified [30] . Such patients may only require ingestion of a snack prior to bedtime to induce postprandial hypotension and transiently lower pressure [12] . Another conservative approach to manage supine hypertension is to raise the head of the bed by 6-9 inches during the night. It has been shown that head-up tilt reduces nighttime pressure natriuresis and improves morning orthostatic tolerance in autonomic failure [31] . This approach should be instituted in all patients, but is not sufficient in patients with severe hypertension, which would necessitate impractical levels of tilt. In most patients, therefore, the addition of pharmacologic agents is required.
There are currently no medications approved for the treatment of hypertension in autonomic failure and, thus, the appropriate choice of medication is often based on small clinical trials in which the primary outcome is short-term efficacy to lower nighttime blood pressure. The ideal pharmacologic agent to treat hypertension in autonomic failure should effectively lower blood pressure during the night, but with a duration of action short enough so that it would not worsen orthostatic hypotension in the morning. On the contrary, it would improve morning orthostatic tolerance by reducing nocturnal pressure natriuresis. Unfortunately, no medication studied so far has met all of these criteria. Transdermal nitroglycerin patches (0.01 mg/h) applied at bedtime and removed in the morning, effectively lower SBP on average by 36 AE 10 mmHg [32] . In contrast, oral administration of other vasodilators including hydralazine (50 mg) and minoxidil (2.5 mg) are less potent, but could still be useful in a given patient [32] . The differences in these treatments may be due to the ability of the nitric oxide donor nitroglycerin to dilate both arteries and veins, whereas other vasodilators act predominantly on arterial vessels. It should be noted that vasodilators would not be first-line antihypertensive treatment if the goal is to prevent end-organ damage because they evoke reflexive increases in sympathetic and renin activity. However, this limitation does not apply to autonomic failure patients due to their loss of baroreflex mechanisms.
Consistent with previous studies showing increased nitric oxide function, nighttime oral administration of 25 mg of sildenafil, a phosphodiesterase-5 inhibitor that potentiates nitric oxide, effectively lowers SBP on average by 52 AE 18 mmHg [27] . The short-acting calcium channel blocker nifedipine (30 mg) also reduces SBP by 37 AE 9 mmHg, but induces natriuresis and may lower standing morning blood pressure [32] . In MSA patients, in whom supine hypertension can be driven by residual sympathetic tone, 0.1 mg of the central sympatholytic clonidine lowers pressure by 26 AE 6 mmHg [33] . Clonidine reduces nocturnal pressure natriuresis but does not improve morning orthostatic tolerance, likely due to residual effects of the medication. Finally, although autonomic failure is associated with very low plasma renin activity, aldosterone levels are preserved [22] . The effectiveness of drugs targeting the renin-angiotensinaldosterone system is currently under investigation in autonomic failure. In summary, even though the ideal antihypertensive agent has not been identified, findings from acute trials suggest that several medications can effectively lower nighttime blood pressure in these patients.
CONSIDERATIONS FOR THE TREATMENT OF SUPINE HYPERTENSION
The finding of hypertensive end-organ damage in autonomic failure patients with supine hypertension has provided a rationale for pharmacologic treatment of this condition. We should recognize, however, that the long-term benefits of this treatment on either end-organ damage or overall prognosis have not been proven, and outcome trials would be impossible to perform. When deciding how aggressive we should be in the treatment of supine hypertension, the patient's prognosis should also be considered. Patients with PAF have a better prognosis and a near-normal life expectancy and, thus, may benefit more from prevention of hypertensive complications. In contrast, patients with MSA have a median survival of approximately 8 years after diagnosis and the clinical picture in later stages is dominated by neurodegenerative symptoms, rather than by orthostatic hypotension or supine hypertension [1, 2, 34] . We should also consider that pharmacologic treatment of hypertension has the potential to aggravate orthostatic hypotension during the night and increase the risk of falling. This is particularly relevant because nocturia is a virtually universal complaint in these patients. Worsening of orthostatic symptoms during the night should be monitored and patients instructed to use a bedside commode. Despite these limitations, treatment of supine hypertension plays an important role in the management of these patients.
These concepts are also relevant to the elderly patient with essential hypertension who develops orthostatic hypotension because of age-related impairment of autonomic function. In these patients, antihypertensive medications are often stopped for fear of worsening orthostatic hypotension, but this is a misguided approach. The incidence of orthostatic hypotension is greater in elderly with uncontrolled hypertension than in those with controlled hypertension [35, 36] . Further, withholding antihypertensive treatment in order to improve orthostatic hypotension often worsens it by promoting pressure diuresis. Thus, it is important that both conditions be treated simultaneously.
CONCLUSION
Although primary autonomic disorders are relatively rare, these patients provide an opportunity to study blood pressure regulation in the setting of profound loss of sympathetic and baroreceptor reflex function. Orthostatic hypotension dominates the clinical picture of autonomic failure and as a result is the focus of most treatment efforts in these patients. However, increasing evidence suggests that the supine hypertension of autonomic failure may also be associated with deleterious consequences and may indirectly worsen morning orthostatic tolerance. Although conservative nonpharmacologic approaches are ideal in these patients, they are often not sufficient to correct the hypertension. Several small clinical studies have provided data that commonly used antihypertensives can effectively lower nocturnal blood pressure in these patients, but none have been able to improve pressure natriuresis or orthostatic tolerance. As autonomic failure patients have exaggerated depressor responses to pharmacologic agents, due to loss of baroreflex buffering, it is necessary to titrate doses to each individual. The need for treatment of supine hypertension should also be determined on an individual basis, taking into account several factors and incorporating overnight blood pressure monitoring rather than single daytime measurements. Finally, MSA and PAF patients provide unique human models of sympatheticdependent and independent hypertension, respectively. As sympathetic activation has long been implicated as a primary determinant of essential hypertension, it is of interest that autonomic failure patients can develop high blood pressure in the absence of sympathetic or renin influences. Understanding the mechanisms driving this paradoxical supine hypertension will have important implications for the treatment of autonomic failure and will improve our knowledge of cardiovascular control in the setting of essential hypertension.
